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ABSTRACT
Persistent pulmonary hypertension of the newborn
(PPHN) is the most common neonatal form and mostly
reversible after a few days with improvement of the
underlying pulmonary condition. When pulmonary
hypertension (PH) persists despite adequate treatment,
the severity of parenchymal lung disease should be
assessed by chest CT. Pulmonary vein stenosis may need
to be ruled out by cardiac catheterisation and lung
biopsy, and genetic workup is necessary when alveolar
capillary dysplasia is suspected. In PPHN, optimisation of
the cardiopulmonary situation including surfactant
therapy should aim for preductal SpO2 between 91%
and 95% and severe cases without post-tricuspid-
unrestrictive shunt may receive prostaglandin E1 to
maintain ductal patency in right heart failure. Inhaled
nitric oxide is indicated in mechanically ventilated infants
to reduce the need for extracorporal membrane
oxygenation (ECMO), and sildenafil can be considered
when this therapy is not available. ECMO may be
indicated according to the ELSO guidelines. In older
preterm infant, where PH is mainly associated with
bronchopulmonary dysplasia (BPD) or in term infants
with developmental lung anomalies such as congenital
diaphragmatic hernia or cardiac anomalies, left
ventricular diastolic dysfunction/left atrial hypertension or
pulmonary vein stenosis, can add to the complexity of
the disease. Here, oral or intravenous sildenafil should
be considered for PH treatment in BPD, the latter for
critically ill patients. Furthermore, prostanoids,
mineralcorticoid receptor antagonists, and diuretics can
be beneficial. Infants with proven or suspected PH
should receive close follow-up, including preductal/
postductal SpO2 measurements, echocardiography and
laboratory work-up including NT-proBNP, guided by
clinical improvement or lack thereof.
INTRODUCTION
Pulmonary hypertension (PH), especially in the
neonate, is a syndrome with multiple possible aetiolo-
gies, leading to challenges in its management. In the
newborn, persistent pulmonary hypertension of the
newborn (PPHN; PH group 1”) is mostly associated
with pulmonary or systemic conditions leading to
acute respiratory failure. In the preterm infant, PH
mainly occurs with chronic lung disease (CLD)
where impaired vascular growth and function results
from prenatal and postnatal injuries. Likewise, other
developmental lung anomalies such as congenital dia-
phragmatic hernia (CDH) can be associated with PH.
Both, the heterogeneity of the disease mechanisms
and the lack of evidence from clinical trials limit the
availability of standardised treatment regimen.
Long-term outcome in infants with PH is largely
unknown. Here, we discuss different pathophysio-
logical aspects of PH in the preterm and term
neonate with acute or chronic lung disease, and pre-
sents expert consensus recommendations on diagnos-
tic and therapeutic approaches.
CLASSIFICATION
As a modification of the Dana Point classification,1
the Nice World Symposium classification of PH2 now
emphasises different conditions of the lungs arising
in the neonatal period associated with the develop-
ment of PH. First, PPHN due to its particular ana-
tomic and physiological nature forms a separate
subcategory in group 1 ‘pulmonary arterial hyperten-
sion’. Second, group 3 ‘pulmonary hypertension due
to lung diseases and/or hypoxia’ now comprises a
subcategory ‘developmental lung diseases’. In this
category, different disease entities are summarised
resulting from abnormalities of the alveolar and vas-
cular compartment or the connective tissue as a con-
sequence of early pre or postnatal injury mechanisms
impacting on lung developmental processes (table 1).
METHODS
The recommendations of this expert consensus
statement are given in table 1. The recommenda-
tions relate to the grading system currently sug-
gested by the European Society of Cardiology
(ESC) and the American Heart Association (AHA),
and were based on data derived from paediatric
studies only (class, level of evidence). The grading
and voting process within the writing group is out-
lined in the executive summary of this online sup-
plement.24 Computerised searches of the PubMed/
MEDLINE bibliographic database from January
1990 to July 2015 were conducted. The developer
searched using the terms ‘pediatric pulmonary
hypertension’, ‘pulmonary hypertension’,
‘neonate’, ‘neonatal chronic lung disease’, ‘bronch-
opulmonary dysplasia’, ‘congenital diaphragmatic
hernia’, ‘nitric oxide’, ‘sildenafil’.
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BACKGROUND ON PH IN THE NEONATE AND INFANT
We focused on expert consensus statements referring to the
most common and most relevant clinical scenarios associated
with PH in the neonate and infant: PPHN (here defined as PH
with failed postnatal decrease in pulmonary vascular resistance
(PVR)), PH associated with CDH/lung hypoplasia, and PH in
bronchopulmonary dysplasia (BPD)/neonatal CLD (nCLD).
The consequence of the first breaths after birth aiming at
establishing functional residual capacity of the lungs is an acute
drop of PVR that allows a subsequent 8-fold to 10-fold increase
in pulmonary blood flow, essential for postnatal gas-exchange
through the lungs. If this physiological adaptation fails, PPHN
can develop.
PPHN as a disease of failed postnatal transition with persistently
high PVR and pulmonary arterial pressure (PAP) has been esti-
mated to occur in 2 per 1000 of live born infants.25 Others have
defined PPHN as a disease occurring during the first 30 days of
life usually presenting at or within a few days after birth.26
Regardless of the definition, the diagnostic evaluation of any
neonate presenting with symptomatic PH outside the first week of
life is critical as the aetiology is likely to exceed the classical PPHN
diagnosis. Chronic progressive PH in the first year of life is now
known to be a distinct condition that is even less well understood
than PPHN, and may occur or worsen with or without a preceding
PPHN episode. This disease can resemble idiopathic PAH of
infancy, which tends to have a poor prognosis.27
PH frequently complicates the course of neonates with
respiratory failure. Known risk factors for the development of
PPHN are (elective) caesarean delivery, meconium aspiration
syndrome, severe respiratory distress due to primary surfactant
deficiency in the preterm infant and sepsis.28 It can occur
without any perinatal risk factor, but is known to complicate
the course of congenital heart diseases. The role of maternal
drug intake such as serotonin reuptake inhibitors in promoting
PPHN remains a matter of debate. Prenatal constriction of the
arterial duct (ductus arteriosus)—sometimes due to exposure to
non-steroidal anti-inflammatory drugs in the third trimester—
may also cause neonatal PH resembling PPHN but with a
restrictive or closed arterial duct.29
PPHN can be a life-threatening complication but is in most
cases reversible within the first few days of life, usually alongside
the improvement of the pulmonary disease it accompanies.
When PPHN does not resolve within 2 weeks of adequate man-
agement and chest CT indicates significant parenchymal lung
disease, alveolar capillary dysplasia (ACD) should be evoked by
lung biopsy (or at autopsy). In ACD, histological findings
include reduction in alveolar capillaries, thickening of alveolar
septal tissue, and lack of sufficient endothelial-epithelial contact.
A few familial cases suggest a possible genetic cause. In addition,
deletions and point mutations within the FOX transcription
factor gene cluster at 16p24.1 were identified.30 Currently, ACD
is incurable, with a maximum reported survival of 3
months,31 32 although ACD occurred up to the age of 6 months
in our own patient population (unpublished).
In congenital diaphragmatic hernia (CDH), PH is present in
most cases, although its pathophysiology is not univocal.
Indeed, lung hypoplasia and the reduction of pulmonary arterial
cross-sectional area, abnormal vasoreactivity to hypoxic episodes
and left heart diastolic dysfunction result in changes of the pul-
monary vascular pressure and blood flow.33 34 The difference
between various contributors to PH development in CDH often
complicates the decision on the best preoperative and surgical
management in the most severe forms of CDH. Likewise, post-
operative PH in CDH requires careful evaluation of all known
variables impacting on PVR as well as pulmonary and systemic
blood flow in these infants.
Table 1 Recommendations for supportive measures and pharmacotherapy in PPHN and PH associated with BPD/nCLD
Recommendations COR LOE
For the treatment of PH in the NICU, the term or preterm newborn infant should receive oxygen, ventilatory support and/or surfactant if needed
to achieve a preductal SpO2 between 91% and 95% when PH is suspected or established; lung hyperinflation and atelectasis, or lung collapse
and intermittent desaturations below 85%, or hyperoxia with preductal SpO2 above 97% should be avoided
3–6
I A
In a newborn infant with acute PPHN in the first hours after birth, a pCO2 between 45 and 60 mm Hg and a target pH >7.25 with lactate
<5 mmol/L can be considered as target values.3–6
IIa B
The preterm and term neonate with severe PH (PPHN) and no post-tricuspid-unrestrictive shunt (e.g, no VSD) may receive Prostaglandin E (PGE)
1 or PGE2 to maintain ductal patency in right heart failure3
IIa B
Intratracheal surfactant can be considered for the preterm and term neonate with PPHN and pulmonary diffusion impairment (but without
congenital diaphragmatic hernia) to optimise ventilation, for example, newborn with meconium aspiration syndrome and PPHN7
IIa B
ECMO can currently not be recommended for the preterm infant <34 0/7 gestational weeks p.m. and/or <2000g body weight, with severe PH8 III B
The preterm infant with respiratory failure should not receive iNO for the prevention of BPD and associated PH, if not enrolled in a rigorously
conducted randomised clinical trial9–11
III A
iNO is indicated for treatment of PPHN in mechanically ventilated newborns to improve oxygenation and to reduce the need for ECMO (a) if
PaO2 is less than 100 mm Hg (while receiving 100% oxygen), or (b) if the oxygenation index exceeds 2512
I A
Oral sildenafil should be considered for treatment of PPHN and PH in BPD, especially if iNO is not available3 13 IIa B
Intravenous sildenafil may be considered for treatment of PH, including PPHN, in critically ill patients, especially in those with an unsatisfactory
response to iNO14 15
IIb B
In the neonate with PPHN or BPD, intravenous prostanoids through a dedicated central line or inhaled iloprost, can be beneficial16–19 IIa B
Treatment of severe PPHN may be extended to ECMO if other intensive care measures fail (http://www.elso.org)8 IIa B
In infants with severe BPD with or without PH, treatment with diuretics, that is, hydrochlorothiazide and spironolactone, can be considered, as
long as cardiac preload is adequate20 21
IIa B
All infants with proven or suspected PH should receive close follow up, including preductal/postductal SpO2 measurements, echocardiography
(one per/week initially, then 1–2/month), and laboratory work-up depending on disease severity including NT-proBNP, BNP, troponin optional,
guided by clinical improvement or lack thereof3 22 23
I C
Recommendations relate to the grading system suggested by the European Society of Cardiology (ESC) and the American Heart Association (AHA), data derived from paediatric
studies only (class, level of evidence).
BPD, bronchopulmonary dysplasia; CLD, chronic lung disease; nCLD, neonatal CLD; COR, class of recommendation; ECMO, extracorporal membrane oxygenation; iNO, inhaled nitric
oxide; LOE, levels of evidence; PH, pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn.
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Table 2 gives an overview over the most important lung devel-
opmental anomalies that are known to are known to be asso-
ciated with PH.
PH associated with BPD/nCLD mainly develops in the
preterm infant. BPD is defined according to Jobe and Bancalari
as oxygen requirement at day 28 of postnatal life or oxygen or
ventilator support at 36 weeks postmenstrual age.35 Risk factors
such as very low birth weight with and without the presence of
intrauterine growth restriction, placental anomalies,
intra-amniotic infections, and postnatal risk factors such as
oxygen toxicity, mechanical ventilation and congenital and
nosocomial infections among others contribute to the develop-
ment of BPD/nCLD. These conditions develop their impact in a
critical developmental window, where the functionally and
structurally immature organ is vulnerable towards the induction
of dramatic and sustained changes determining postnatal respira-
tory outcome. The pathobiology and clinical course of BPD/
nCLD has changed in the postsurfactant era: The disease is now
characterised by (1) impaired alveolarisation with fewer, larger
and simplified alveoli, alongside with (2) disturbed vasculogen-
esis resulting in fewer (small, intra-acinar) pulmonary arteries.
Bronchial smooth muscle thickening, interstitial oedema, fibrosis
and inflammation known from the presurfactant era can also be
found in the new form of the disease. Associated with defective
vascular function and structure the reduction in vascular surface
area can result in pulmonary hypertensive vascular disease that
impacts short and long-term survival and is characterised by pul-
monary arteriolar muscularisation, vessel loss, and right ven-
tricular (RV) hypertrophy, among other findings.
In concert with the different pre and postnatal risk factors
indicated above, the presence of alveolar hyperoxia (and
hypoxia resulting from frequent desaturations) as well as mech-
anical stretch lead to the structural remodelling of the pulmon-
ary vasculature. Beyond the neonatal period, increased
pulmonary vascular tone and heightened vasoreactivity may
contribute to sustained PH and potentially increase the risk for
late PH associated with (n)CLD.
Although PH predominantly develops in the very low birth
weight and very preterm infant, some infants develop late onset
PH after a couple of weeks.22 36 37 Furthermore, the moderate
but growth-retarded preterm infant has been shown to develop
PH in a considerable number of cases.36 A crucial and unre-
solved question in neonates and infants with BPD is the optimal
time for PH screening by echocardiography. At the same time,
the best diagnostic tool to detect PH in patients with BPD is still
a matter of debate, as the non-invasive evaluation by echocardi-
ography has been shown to lack sensitivity compared with the
invasive procedure of cardiac catheterisation in these patients.
Finally, the prediction of late PH by the presence of early
disease in the preterm infant is still questionable. Certainly,
patients with BPD with late PH need careful evaluation and a
minimisation of hypoxic episodes.38 Furthermore, the persist-
ence of PH in these and other patients should lead to the
consideration of cardiac catheterisation and specific imaging
techniques, that is, CT and/or cardiac MRI to rule out pulmon-
ary vein stenosis. It has to be considered that pulmonary
capillary haemangiomatosis (PH group 1’) may be diagnosed at
a wide age range, and may clinically be indistinguishable
from pulmonary veno-occlusive disease (PH group 1’) or PAH
(PH group 1).
Prognosis and outcome of PH in BPD/nCLD
Approximately one in four infants with moderate-to-severe BPD
is known to develop PH,39 triggered by the complex interplay
of inflammatory processes, stretch and oxygen toxicity
side-by-side with recurrent alveolar hypoxia leading to endothe-
lial dysfunction. The development of PH in BPD is not only an
epiphenomenon or minor secondary event, but appears to
greatly increase mortality with an estimated death rate of 47%
2 years after PH diagnosis.40 Furthermore, with an increasing
percentage of extremely immature infants surviving in the post-
surfactant era, BPD is one of the most common primary diagno-
ses in neonatal follow-up care and frequently seen in paediatric
PH clinics today. BPD as a major etiologic factor for PH
Table 2 Developmental lung diseases associated with pulmonary hypertension
Developmental defect Vascular pathology
Alveolar capillary dysplasia (ACD) with or without misalignments of veins (MPV) Genetic disorder associated with an abnormal development of the capillary vascular
system around the alveoli of the lungs
Bronchopulmonary dysplasia (BPD) Prenatal and postnatal impact of exogenous risk factors on a structural and functional
immature lung lead to postnatal impairment of angiogenesis and alveolarisation
associated with abnormal vascular function (increased tone, altered reactivity, impaired
metabolism) and structure (smooth muscle cell proliferation, altered extra cellular matrix
structure)
Congenital diaphragmatic hernia Developmental defect leading to severe vascular remodelling and rarefication of the
vascular bed
Lung hypoplasia (primary and secondary) Genetic abnormalities or severe reduction in amniotic fluid leading to reduced prenatal
alveolar and vascular development
Pulmonary interstitial glycogenosis Rare non-lethal paediatric form of interstitial lung disease, possible male predominance.
Infants present with respiratory distress. Histological characteristics are the accumulation
of monoparticulate glycogen in interstitial cells and associated lung growth abnormalities
affecting all lung structures
Pulmonary alveolar proteinosis Rare lung disease in which abnormal accumulation of surfactant occurs within the
alveoli, interfering with gas exchange and affecting lung growth. Possible cause
anti-GM-CSF autoantibodies
Pulmonary lymphangiectasia Rare developmental pulmonary disorder characterised by pulmonary subpleural,
interlobar, perivascular and peribronchial lymphatic dilatation
Surfactant protein (SP) abnormalities (SP-B and SP-C deficiency, ATP binding
cassette A3 mutation, thyroid transcription factor 1/Nkx2.1 homeobox mutation)
Genetic inheritance of surfactant deficiency leading to impaired lung development
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development has been recognised and, in fact, was assigned its
own category in the recently published classification of paediat-
ric pulmonary hypertensive vascular disease (category 4: BPD;
PVRI Panama classification, 2011).26
DIAGNOSIS AND MONITORING OF PH ASSOCIATED WITH
ACUTE OR CHRONIC LUNG DISEASE IN THE PRETERM AND
TERM NEONATE AND INFANT
Diagnosis and monitoring of existing or developing PH is crit-
ical in PPHN as well as in PH associated with developmental/
parenchymal lung diseases. High resolution chest CTwith angi-
ography is a key non-invasive diagnostic tool for assessing the
underlying lung disease beyond chest X-ray41 and needs to be
considered in cases where other diagnostic tools do not suffice.
Regarding the diagnosis of PH by echocardiography and cath-
eterisation we refer to other publications in this special
issue.42 43
In general, transthoracic echocardiography should be per-
formed initially and once or twice per month in all infants with
clinical suspicion of PH. The latter is fulfilled with increased
oxygen requirement or hypoxaemia, gradual increase in ventila-
tor settings or oxygen requirement and clinical signs of RV dys-
function. In infants treated for acute PH or undergoing weaning
from PH, echocardiography should be pursued twice a week in
combination with serum BNP/NT-proBNP. In infants with BPD
after discharge, regular or continous measurements of oxygen
saturation should accompany oxygen weaning in infants with
BPD, at the upper and lower extremities. Echocardiography
should be performed (a) every 3 months in infants with BPD in
need of additional oxygen supply or those at strong risk for PH;
(b) every 3–6 months in children at risk, that is, infants with
growth retardation, very low birth weight, MV/CPAP >28th
day of life, BPD, failure to thrive despite adequate caloric
intake. Cardiac MRI can be considered, if available and if strong
clinical suspicion for PH with ventricular dysfunction is present.
Serum BNP or NT-proBNP are frequently used as monitoring
and outcome biomarkers for children with diagnosed PH, but
increased concentrations due to high systemic blood pressure,
persistent ductus arteriosus (PDA), renal failure, or left ventricu-
lar dysfunction can be a confounder. All infants with persistent
PH despite optimal management of lung disease, before starting
chronic pulmonary vasodilator therapy, should probably
undergo cardiac catherisation,3 22 23 40 unless clinical circum-
stances skew the risk-benefit ratio.
THERAPY OF PH ASSOCIATED WITH ACUTE OR CHRONIC
LUNG DISEASE IN THE PRETERM AND TERM NEONATE
AND INFANT
General treatment measures for PPHN in the term and
preterm neonate
Usually, the course of PPHN is favourable. First, exposure to
environmental factors that worsen PPHN including handling,
tracheal suction, heel pricks and others have to be minimised or
avoided, if possible. Furthermore, polycythaemia increasing
blood viscosity and increased PVR should be corrected
(figure 1).
Mechanical ventilation strategies need to aim for adequate
lung recruitment and alveolar ventilation by avoiding overinfla-
tion of the lungs as well as high mean airway pressures to
prevent both, pulmonary barotrauma and volutrauma. The goal
is to maintain preductal SaO2 over 85%, and PaCO2 in the
range of 40–55 mm Hg. Optimisation of the acid-base balance
(pH range 7.45–7.55) to control PVR may require repetitive
doses of sodium bicarbonate, although this therapy needs to be
considered with caution due to its known side effects and lim-
itations. Furthermore, appropriate fluid management, cardiovas-
cular resuscitation and use of pulmonary vasodilators should be
considered (5). Supporting cardiovascular function remains a
major goal in PPHN management. Early initiation of inotropic
and vasoactive agents to increase cardiac output, maintain
adequate blood pressure and enhance oxygen delivery to the
tissue is preferred.
The application of the locally vasodilative inhaled nitric oxide
(iNO) is the mainstay of PPHN therapy in most cases.
Intravenous vasodilators such as epoprostenol and treprostinil
may be considered and should be given through a central
venous line of the upper body, but can worsen the clinical con-
dition by creating V/Q mismatch and intrapulmonary shunt
resulting in profound desaturations. In all cases, a rigorous clin-
ical and echocardiographic assessment is required for diagnosis
and monitoring of biventricular systolic and diastolic function.
Pharmacological and extracorporal membrane oxygenation
treatment for PPHN
Infants with significant right-to-left shunting require pulmonary
vasodilator therapy. iNO is presently recommended for infants
with PPHN12 as it improves outcome in the hypoxemic term
and near term infant by reducing the incidence of the combined
endpoint death or need for extracorporal membrane oxygen-
ation (ECMO). Oxygenation improves in approximately 50% of
infants receiving iNO.12 Usual concentrations of iNO
range from 5 to 20 ppm to treat PPHN, with the typical starting
dose being 20 ppm. As a preventive measure for the develop-
ment of acute or chronic PH in the preterm infant with respira-
tory failure, the use of iNO cannot be recommended outside
randomised controlled trials.9 10 In patients with CDH, iNO
may be considered for bridging to ECMO (oxygenation
index>20 or saturation differences >10%; oxygenation index
(OI): FiO2%×MAP/pO2) although no beneficial effects could
be shown for this patient cohort.44
ECMO may be required to ensure effective oxygenation and
decarboxylation while limiting barotrauma and volutrauma of
the lung and to improve right heart failure. ECMO is indicated
when hypoxaemia persists in spite of optimal medical manage-
ment according to the following criteria:
▸ Preductal SpO2 <85% despite peak inspiratory pressure
>28 cmH2O (or mean airway pressure >15 cmH2O with
high frequency oscillation),
▸ PPHN and circulatory failure resistant to adequate
management,
▸ Gestational age >34 weeks,
▸ Birth weight >2 kg.
Additional ECMO criteria have been proposed with consist-
ent OI ≥40, systemic hypotension resistant to fluid and ino-
tropic therapy, urine output <0.05 mL/kg/h for 12–24 h and
metabolic acidosis (lactate ≥5 mmol/L, pH <7.15). See also the
ELSO guidelines for ECMO.45
There is limited experience for the application of systemic
medication used in PAH in patients with PPHN.
Phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil may be
potentially useful as an increase in PDE-5 activity contributes to
the pathophysiology of PPHN. Evidence exists that sildenafil is
well tolerated in the newborn with PPHN.14 It is applied
via feeding tube in a starting dose of 0.5–1 mg/kg/dose every
6 h.46–48 64 Meta-analysis of three trials including 77 newborns
with PPHN indicated that sildenafil may improve oxygenation
and reduce mortality.14 These results suggest that sildenafil has
significant potential for PPHN treatment, especially in settings
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where iNO is not available. Nonetheless, systemic pulmonary
vasodilator treatment has to be considered with caution as wor-
sening of the ventilation-perfusion mismatch hypoxia and sys-
temic hypotension may occur, especially in the preterm
infant.3 49 In CDH, intravenous sildenafil can be considered in
case of suprasystemic PAP and right-to-left shunting.
Prostacyclin and analogues have been used in PPHN but evi-
dence is limited as only a few case reports or short series are
Figure 1 Algorthm with the current recommendations for the diagnosis, monitoring and treatment of persistent pulmonary hypertension of the
newborn (PPHN). ^PH needs to be considered when tricuspid regurgitation (TR) jet >2.5m/sec (Echo) and preductal/postductal oxygen saturation
differences >10%. ^^https://www.elso.org/Portals/0/IGD/Archive/FileManager/8588d1a580cusersshyerdocumentselsoguidelinesfo
rneonatalrespiratoryfailure13.pdf. ECMO, extracorporal membrane oxygenation; iNO, inhaled nitric oxide; PGE1, prostaglandin E1; PPHN, pulmonary
hypertension of the newborn; RV, right ventricle; TR, tricuspid regurgitation.
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available. The use of epoprostenol in term and preterm infants
requires a central line and careful management of systemic
effects.50
Finally, there is increasing evidence that endothelins contrib-
ute to PH in the neonate. Although, recent case reports and
earlier studies suggest that bosentan may improve PPHN, there
is still insufficient evidence to generally recommend the use of
bosentan to manage PPHN.51 52 The yet unpublished
FUTURE4 trial on bosentan in PPHN showed negative results,
may be due to poor intestinal resorption of oral bosentan in
neonates.
In the case of imminent RV failure, the (re-) opening of the
ductus arteriosus by the use of prostaglandin E1 (PGE1) or even
stenting of the persistent ductus arteriosus (PDA) may be consid-
ered to decompress the RV, leading to a decrease in SaO2
measured in the lower extremities53 Figure 1 provides a sche-
matic overview over treatment and monitoring measures in the
infant with PPHN.
Treatment of chronic PH in BPD/nCLD
Supplemental oxygen therapy is the common treatment option
for PH associated with BPD/nCLD where target systemic arterial
oxygen saturation is >93% for all premature infants and >95%
for infants with proven PH (figure 2). Serial echocardiograms
and cardiac catheterisation is recommended to determine PAP
and PVR.4 Atrial or ventricular shunts are not well tolerated in
children with nCLD and may be related to the smaller vascular
surface area in relation to body size and cardiac output, where a
mild increase in pulmonary blood flow may indicate a significant
shunt.4
Figure 2 Algorithm with the current recommendations for the management of pulmonary hypertention in the newborn with bronchopulmonary
dysplasia (BPD)/neonatal chronic lung disease (nCLD).
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In infants with severe BPD, treatment with diuretics, that is,
hydrochlorothiazide and spironolactone can be considered,
especially when volume overload is evident.20 54 Spironolactone
may have additional benefits in neonates and young infants due
to mineralocorticoid blockade in RV hypertrophy and PH and
can improve lung mechanics in BPD.55
Pulmonary vasodilators/PAH specific medication
Long-term therapy may be considered after careful evaluation
and exclusion of associated anomalies such as a left-to-right
shunt, left ventricular diastolic dysfunction and pulmonary
vein stenosis. However, published data do not provide suffi-
cient evidence to allow for general recommendations.
Therefore, careful considerations for the use of targeted
therapeutic approaches together with consequent and timely
re-evaluations are advised. It has to be noted that all PAH-
targeted drugs have to be declared ‘off-label use’ in the
neonate and infant with PH associated with BPD/nCLD.
Of the three current potential target pathways for PH treatment
in BPD/nCLD, the widest experience is reported for the modula-
tion of the NO signalling pathway with the PDE-5-inhibitor silde-
nafil. With oral sildenafil, significant improvement of PAP could
be demonstrated in children under the age of 2 years with nCLD
and PH.56 Intravenous sildenafil may be advantageous in sick
infants when enteral bioavailability is unclear. Furthermore,
repetitive (or potentially continuous) application of inhaled ilo-
prost can be used in patients with BPD.57–59 As endothelin is a
potent pulmonary vasoconstrictor and increased in BPD and
hyperoxia,51 60 61 bosentan treatment may also be considered in
PH associated with BPD/nCLD, although only case reports are
available for these infants.60 62 63 64
Very potent intravenous vasodilators, such as epoprostenol or
treprostinil, can be considered but need to be given through a
central venous line (upper body line preferred). Their use may
be limited due to the adverse effects with systemic hypotension,
potential V/Q mismatch and intrapulmonary right-to-left
shunting with consecutive hypoxaemia Figures 1 and 2 provide
schematic overviews over treatment and monitoring measures in
the infant with PPHN or PH in BPP/NCCD. Over the current
recommendations for the treatment of pulmonary hypertension
(PH) in chronic lung disease of the preterm and term infant.
CONCLUSIONS
PPHN is a condition in term neonates that may or may not have
prenatal origins, and often complicates acute respiratory failure
in the first 1–2 weeks after birth. As the course of the disease
can be extremely severe, rigorous treatment regimen is manda-
tory to improve disease outcome. Since iNO and ECMO are
effective in the majority of the cases and only limited evidence
for the efficacy of oral or intravenous medications for PPHN
treatment is available, the importance of any additional,
so-called ‘PH specific’ medication in the armamentarium for PH
treatment needs to be defined for this patient cohort. In the
preterm infant, PH is rare in the first 4 weeks of postnatal life,
but may develop along with nCLD, that is, BPD, where vascular
dysfunction and alveolar hypoxia perpetuate disease develop-
ment. Management of PH in developmental lung diseases is
mainly focused on the optimisation of systemic oxygenation.
Evidence is still lacking for the use of medications available for
pulmonary arterial hypertension treatment in the neonatal or
former preterm cohort. Thus, a thorough evaluation of PH and
its underlying mechanisms is mandatory before targeted PH
therapy on a case-by-case basis. Long-term outcome related to
PPHN and PH associated with developmental lung diseases
remains mostly unknown, pointing to the need for prospective
and controlled studies in population-based cohorts.
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